Research programme: eye disorder therapies - ExonHit Therapeutics

Drug Profile

Research programme: eye disorder therapies - ExonHit Therapeutics

Alternative Names: EHT 0203; EHT 0204; EHT 203; EHT 204

Latest Information Update: 04 Jul 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ExonHit Therapeutics
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Eye-Disorders

Most Recent Events

  • 19 Dec 2012 ExonHit Therapeutics has merged with InGen Biosciences to form Diaxonhit
  • 21 Aug 2009 Discontinued - Preclinical for Eye disorders in France (PO)
  • 18 Mar 2008 This programme is still in active development for Eye disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top